Date: 2013-05-17
Type of information: Fundraising
Company: ElsaLys Biotech (France)
Investors: Transgene (France) Sofimac Partners (France)
Amount: € 2.1 million
Funding type: first round of financing
Planned used:
Others: ElsaLys Biotech, a new french player in the therapeutic monoclonal antibody arena, has announced a first round of financing of 2.1M€ with Transgene and Sofimac Partners. This spin-off from Transgene R&D will develop novel monoclonal antibodies against first-in-class targets for the treatment of cancer & inflammatory diseases. Dr Jean-Yves Bonnefoy, former VP, R&D of Transgene is CEO of ElsaLys Biotech and President in office of Alsace BioValley competitiveness cluster. In the short term, ElsaLys Biotech will focus on the development of antibodies against targets derived from academic collaborators up to characterized drug candidates with robust in vivo proof of concept. Further clinical development will be conducted through industrial partnerships.
The company aims to bring a first antibody drug candidate to IND enabling studies within the next three years. All co-founders of ElsaLys Biotech come from Transgene. Next to Dr Jean-Yves Bonnefoy, Dr Christine Guillen, formerly Manager of External R&D collaborations at Transgene, is the new COO of ElsaLys Biotech. Today, the portfolio of ElsaLys Biotech is composed of 4 novel projects issued from well-known academic groups and partners such as EFS, Curie Institute, Tumor Institute of Turin and SATT-Sud Est.
Based in Lyon & Illkirch Graffenstaden, ElsaLys Biotech will benefit from unique environments within the clusters Lyon Biopole & Alsace BioValley.
Therapeutic area:
